Nature Clinical Practice Rheumatology

 
 
  • Science As Experiment; Science As Observation This Viewpoint discusses the strengths and limitations of both observational studies and randomized controlled trials.
  • Treatment With Rasburicase of a Tophaceous Gout The treatment of gout in patients who are allergic to allopurinol can be considered a therapeutic challenge. This Case Study highlights the diversity of medications that can be used to manage hyperuricemia in this situation.
  • Glucocorticoid Therapy in Rheumatoid Arthritis aim of this study was to compare the safety and efficacy of intra-articular versus intramuscular glucocorticoid on outcomes in patients with RA.
  • Chinese Antirheumatic Remedy for the Treatment of SLE This study investigates the potential of ethyl acetate extract of the Chinese antirheumatic remedy Tripterygium wilfordii Hook F (TwHF) as a novel therapeutic approach in SLE patients.
  • Is Abatacept an Effective Treatment for RA Patients? The aim of this study was to determine whether abatacept is a safe and effective method of treatment for patients with RA who have been unresponsive to previous anti-TNF treatment.
  • Infliximab Increases Bone Mineral Density TNF agents have been shown to increase BMD and this open-label study evaluates its efficacy on on BMD.
  • Therapeutics of Wegener’s Granulomatosis Although effective at inducing and maintaining remission in most patients with Wegener's granulomatosis, agents such as cyclophosphamide and high-dose glucocorticoids are associated with severe toxic effects. In this Review, the authors discuss the progress that is being made in the search for alternative treatments for this common form of systemic vasculitis.
  • Should Patients with Early RA be Prescribed Combination Therapy? The largest study of its kind to date has reported that a combination of disease-modifying antirheumatic drugs and low-dose prednisolone safely ameliorates joint damage and symptoms of rheumatoid arthritis over 2 years. John Kirwan discusses the implications for the treatment of early rheumatoid arthritis, and for future approaches to treating established disease.